Premium
Rationale and Experience in Treating Suspected Hospital‐Based Mixed Infections
Author(s) -
Billeter Marianne
Publication year - 1995
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1995.tb04343.x
Subject(s) - medicine , formulary , intensive care medicine , ticarcillin , antimicrobial , pharmacy , dosing , adverse effect , regimen , antibiotic resistance , antibiotics , family medicine , imipenem , microbiology and biotechnology , biology , chemistry , organic chemistry
Ochsner Foundation Hospital of the Ochsner Medical Institutions (OMI), a 532‐bed tertiary care facility in New Orleans, uses a formulary review process common to many institutions. Considered in the selection of antimicrobial therapy are efficacy, safety, and cost. At OMI, ticarcillin‐clavulanate plus gentamicin are the standard broad‐spectrum antimicrobial agents for initial treatment of suspected mixed infections. The pharmacy department provides an aminoglycoside‐monitoring program and convenient dosing guidelines. The regimen has resulted in good therapeutic outcomes and few adverse effects. Bacterial resistance has not been detected. Future plans include a large‐scale concurrent review of patient outcomes, resistance patterns, and rates of fungal overgrowth associated with these agents.